{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:46:47Z","timestamp":1792417607124,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T00:00:00Z","timestamp":1397606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.cjca.2014.02.012","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T18:16:05Z","timestamp":1393352165000},"page":"S16-S22","source":"Crossref","is-referenced-by-count":54,"special_numbering":"S","title":["\u03b2-Blockers in Hypertension: Studies and Meta-analyses Over\u00a0the Years"],"prefix":"10.1016","volume":"30","author":[{"given":"Pierre","family":"Larochelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon W.","family":"Tobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Lacourci\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2014.02.012_bib1","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should \u03b2-blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.02.012_bib2","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1503\/cmaj.060110","article-title":"Re-examining the efficacy of \u03b2-blockers for the treatment of hypertension: a meta-analysis [erratum in 2007;176:976]","volume":"174","author":"Khan","year":"2006","journal-title":"CMAJ"},{"issue":"5\u00a0suppl","key":"10.1016\/j.cjca.2014.02.012_bib3","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.cjca.2014.01.006","article-title":"Atenolol vs nonatenolol \u03b2-blockers for the treatment of hypertension: a meta-analysis","volume":"30","author":"Kuyper","year":"2014","journal-title":"Can J Cardiol"},{"issue":"5 suppl","key":"10.1016\/j.cjca.2014.02.012_bib4","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.cjca.2013.12.001","article-title":"Contemporary use of \u03b2-blockers: clinical relevance of subclassification","volume":"30","author":"Poirier","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2014.02.012_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2710.2006.00699.x","article-title":"The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients","volume":"31","author":"Ismail","year":"2006","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.cjca.2014.02.012_bib6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2125.2006.02796.x","article-title":"The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension","volume":"63","author":"Lefebvre","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2014.02.012_bib7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2217\/pgs.11.20","article-title":"Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics","volume":"12","author":"Sehrt","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cjca.2014.02.012_bib8","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.ehj.2004.06.002","article-title":"Expert consensus on beta-adrenergic receptor blockers of European Society of Cardiology","volume":"25","author":"Lopez-Sendon","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2014.02.012_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1258\/smj.2011.011274","article-title":"The impact of beta blockers on mortality in stable angina: a meta analysis","volume":"57","author":"Huang","year":"2012","journal-title":"Scott Med J"},{"key":"10.1016\/j.cjca.2014.02.012_bib10","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.1982.03320370021023","article-title":"A\u00a0randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results","volume":"247","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2014.02.012_bib11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM198104023041401","article-title":"Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction","volume":"304","year":"1981","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2014.02.012_bib12","first-page":"224","article-title":"A\u00a0comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"308","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.02.012_bib13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0895-7061(96)00014-3","article-title":"Calcium antagonists: not appropriate as first line antihypertensive agents","volume":"9","author":"Furberg","year":"1996","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2014.02.012_bib14","first-page":"1967","volume":"288","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2014.02.012_bib15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2012.10.011","article-title":"Meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure","volume":"61","author":"Savarese","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.02.012_bib16","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients","volume":"33","author":"Van Vark","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2014.02.012_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bmj.291.6488.97","article-title":"MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party","volume":"291","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.cjca.2014.02.012_bib18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00004872-198508000-00011","article-title":"The IPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertensives (IPPSH)","volume":"3","year":"1985","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2014.02.012_bib19","first-page":"1282","article-title":"Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)","volume":"338","author":"Dalh\u00f6f","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.02.012_bib20","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality the Swedish Trial in Old Patients with Hypertension-2 study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.02.012_bib21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00004872-198710000-00009","article-title":"Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY Trial","volume":"5","author":"Wilhelmsen","year":"1987","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2014.02.012_bib22","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1001\/jama.1988.03720130040027","article-title":"Primary prevention with metoprolol in patients with hypertension","volume":"259","author":"Wikstrand","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2014.02.012_bib23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Primary Prevention Project (CAPPP) randomized trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.02.012_bib24","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2014.02.012_bib25","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/bmj.293.6555.1145","article-title":"Randomised trial of treatment of hypertension in elderly patients in primary care","volume":"293","author":"Coope","year":"1986","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2014.02.012_bib26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.304.6824.405","article-title":"The Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party","volume":"304","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2014.02.012_bib27","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2014.02.012_bib28","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","article-title":"Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial","volume":"106","author":"Zanchetti","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.02.012_bib29","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dalh\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.02.012_bib30","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A\u00a0calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2014.02.012_bib31","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial","volume":"289","author":"Black","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2014.02.012_bib32","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dalh\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.02.012_bib33","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/CIRCULATIONAHA.105.595496","article-title":"Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFE) study","volume":"113","author":"William","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.02.012_bib34","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.279.23.1903","article-title":"Are \u03b2-blockers efficacious as first-line therapy for hypertension in the elderly?","volume":"279","author":"Messerli","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2014.02.012_bib35","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(01)06411-X","article-title":"Cardiovascular protection and blood reduction: a meta-analysis","volume":"358","author":"Staessen","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.02.012_bib36","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(04)17355-8","article-title":"Atenolol in hypertension: is it a wise choice?","volume":"364","author":"Carlberg","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2014.02.012_bib37","first-page":"CD002003","article-title":"Beta-blockers for hypertension","volume":"11","author":"Wiysonge","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cjca.2014.02.012_bib38","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/bmj.39548.738368.BE","article-title":"Effects of different regimens on major cardiovascular events in older and younger adults: meta-analysis of randomised trials","volume":"336","author":"Turnbull","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2014.02.012_bib39","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure-lowering drugs in the prevention of cardiovascular disease: meta-analysis randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2014.02.012_bib40","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cjca.2012.04.001","article-title":"The evolving role of \u03b2-adrenergic receptor blockers in managing hypertension","volume":"28","author":"Poirier","year":"2012","journal-title":"Can J Cardiol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X14001068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X14001068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T06:52:27Z","timestamp":1538808747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X14001068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0828282X14001068"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2014.02.012","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}